Genomics Reporting Implementation Guide
2.0.0 - trial-use

This page is part of the Genetic Reporting Implementation Guide (v2.0.0: STU 2) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Example Task: PGxRecEx04

Generated Narrative

Resource "PGxRecEx04"

Profile: Followup Recommendation

status: requested

intent: proposal

code: Decrease dose (LOINC#LA26422-8)

description: For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.

for: Patient/CGPatientExample01 " EVERYMAN"

reasonReference: Observation/TxImp04: Poor metabolizer